Drug Discovery World

MAY 30, 2024

Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial? It is these differences in immune response, which have stimulated our research to improve vaccine design.

Vaccine 147

Vaccine Protein Expression Clinical Trials Immune Response 147

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Target Review

JANUARY 23, 2024

Cell-based therapies, such as tumour-infiltrating lymphocyte (TIL) therapy, have also drawn significant attention following promising results in a melanoma trial. Individualised cancer vaccines are tailored to each patient’s tumour, helping the immune system mount cancer-specific immune responses that can boost checkpoint inhibitor efficacy.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. It forms part of the UK Recovery Trial, which found that a cheap steroid called dexamethasone could save lives. We need to know, and the way to know is to do the trials that will tell us whether that hope turns into reality.”.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners. Overall, in-hospital mortality was 12.9

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. The trial on 10,000 people will now see if the vaccine can prevent people getting ill. The Novavax jab is only the second to enter large scale trials in the UK; the other has been developed by the University of Oxford.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. No new safety signal for Calquence was observed in the trials. No new safety signal for Calquence was observed in the trials.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. The city is host to many innovative biotech companies, including relative newcomers Orexa, a company that recently launched its first Phase II clinical trial.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Drug Discovery World

APRIL 20, 2023

SARS-CoV-2 particles spread through the respiratory mucosa and other infected cells, causing changes in peripheral immune cells and eliciting a cascade of immune responses, resulting in a detrimental cytokine storm. Acute and persistent symptoms in non-hospitalized PCR- confirmed COVID-19 patients,” Sci Rep, vol.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

JANUARY 22, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus 52

Virus Immune Response Disease Clinical Trials 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. Cutting through the usual red tape and working with an intense sense of purpose, the partnership took a mere matter of weeks to set up its first four clinical trials. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

The Pharma Data

NOVEMBER 18, 2020

. “Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833.” Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 8, 2020

The efficacy rating followed an interim report of ongoing human trials conducted in that country, CNBC reported. In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. The vaccine was also demonstrating a strong safety profile.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. TARRYTOWN, N.Y. , 28, 2020 /PRNewswire/ — . Regeneron has shared these results with the U.S. Regeneron has shared these results with the U.S.

Virus 40

Virus Trials Clinical Trials Production 40

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” In addition to this alliance, we also conduct our own research and participate in clinical trials to bring the benefits of medical research to the community level.

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

The Pharma Data

OCTOBER 16, 2020

Immune Responses Long-Lasting After Serious COVID-19. NIH Launches Trial of Antibody Drugs Against COVID-19. 14, 2020 — A study to assess whether certain approved or experimental drugs are effective against COVID-19 and warrant testing in large clinical trials has been launched by the U.S. WEDNESDAY, Oct.

Hospitals 52

Hospitals Immune Response Vaccine Trials 52

Broad Institute

OCTOBER 4, 2023

Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Small Molecule 128

Small Molecule Clinical Trials Engineering Medical Schools 128

The Pharma Data

OCTOBER 26, 2020

FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Novavax will present data from an ongoing Phase I/II clinical trial, including new Phase II reactogenicity data from its COVID-19 vaccine candidate.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * About VAT08 and VAT02 The Phase 3 trial, VAT08 is evaluating a 10µg antigen formulation of the SARS-CoV-2 adjuvanted recombinant protein-based vaccine?for

Vaccine 52

Vaccine Virus Trials Immune Response 52

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations 91

Regulations Engineering Clinical Trials DNA 91

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

Agency IQ

DECEMBER 1, 2023

Furthermore, the guidance offered a list of updated clinical outcome measures and offered insight on FDA’s evolving view of decentralized clinical trials and the use of real-world data to supplement trials. Lastly, the revised guidance briefly discussed trials meant to assess drugs intended for prevention of Covid-19.

FDA 40

FDA Clinical Trials Vaccine Trials 40

The Pharma Data

JANUARY 3, 2021

This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. The last patients in the trial received their final dose on 21 December 2020. The topline data from the trial is expected to be available in January 2021.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

Drug Discovery World

APRIL 14, 2023

Melissa M Hudson, MD – Joseph H Burchenal Award for Outstanding Achievement in Clinical Cancer Research Hudson is a faculty member, Director of the Cancer Survivorship Division, Associate Director, Population Sciences, and The Charles E Williams Endowed Chair of Oncology-Cancer Survivorship at St Jude Children’s Research Hospital.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

AUGUST 9, 2021

The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus. ” While injectable vaccines are offering significant reduction in hospitalization and death, there is currently no registered intranasal vaccine against COVID-19. .”

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. adult participants from the Phase 1 trial of the two-dose series. today announced that they have submitted Phase 1 data to the U.S.

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

JANUARY 17, 2021

The NDA was built on data from the Phase III VICTORIA trial. The primary endpoint of the study was composite of time to first occurrence of heart failure hospitalization or cardiovascular death. The NDA was supported by results from two pivotal trials, Phase III AURORA and Phase II AURA-LV.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” mg and 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccine Immune Response Clinical Trials 40

The Pharma Data

DECEMBER 16, 2020

Instead, it uses a genetic code, which tricks the body into developing an immune response to the virus. Moderna’s vaccine has not been used outside of clinical trials, while Pfizer and BioNTech’s vaccine has already been rolled out in Britain. Most Read Today. Source link.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

JANUARY 11, 2021

In clinical trials, it could detect COVID-19 with 90%+ accuracy in about two minutes. . By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . I-SPY COVID-19 is assessing multiple drugs for critical COVID-19 hospitalized or ICU patients.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

MARCH 25, 2021

Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. About the Phase 3 TIDES (DEN-301) Trial. With limited options to prevent the disease, there is a pressing need for widely available dengue vaccines.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

JANUARY 4, 2021

Data from Moderna’s trials showed that people between 18 and 55 who received two 50-microgram doses had an “identical immune response” to the standard of two 100-microgram doses, Dr. Moncef Slaoui explained, the Times reported. But a faster-spreading virus could swamp hospitals with seriously ill patients.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The researchers had been intrigued by an earlier clinical trial testing the ACE2 decoy strategy [2]. However, in this earlier attempt, the clinical trial found no reduction in mortality. If all goes well, they hope to move their ACE2 decoy into a clinical trial.

Virus 52

Virus Clinical Trials Engineering Immune Response 52